CSL shares have rallied 26% in a month amid a cautious earnings recovery outlook for FY27, with industry analysts divided on the stock’s near-term prospects amid ongoing restructuring and product pipeline developments.
CSL shares have bounced back strongly after a bruising year, but investors are now asking a harder question: whether the earnings recovery can keep pace with the market’s renewed enthusiasm.
The Australian biotech giant has risen about 26% over the past month, even though it remains down roughly 17% over the past 12 months. That rebound has been striking after the stock briefly sank to levels not seen in more than a decade. According to CSL’s annual report, the latest full-year results were dominated by a US$2.6 billion statutory loss, driven mainly by non-cash impairments and restructuring charges, while underlying NPATA slipped 2% to US$3.1 billion on revenue of US$15.8 billion, down 1%. The company also maintained a dividend and completed a A$1 billion buy-back.
The sharp sell-off earlier this year reflected fears that CSL’s earnings were deteriorating more quickly than they were. But the FY26 result gave investors a clearer base from which to judge the business, particularly after heavy write-downs tied to CSL Vifor. The focus now has shifted to FY27, where management is guiding to about 5% growth in underlying net profit after tax, ahead of current market expectations of roughly 2%. Behring remains the main engine of growth, with immunoglobulin sales expected to rise at a mid-to-high single-digit pace, while Vifor is still a drag as generic competition pressures its iron medicines.
That mismatch between the stronger core business and the weaker smaller unit is central to the investment case. Stock analysis data shows CSL recently traded near A$167, implying a forward price-to-earnings ratio of about 19 times. That is not cheap, but it may be justified if earnings do recover as expected. The same data shows a dividend yield of about 2.4% and relatively low volatility compared with the broader market.
Broker views remain broadly supportive, though not unanimous. UBS has a buy rating and a target of A$181, Morgan Stanley rates the stock overweight with a target of A$182, and Morgans has a buy call with a target of A$187.71. Macquarie is more cautious, with a neutral rating and a target near A$133. CSL’s investors are also watching the company’s product pipeline, including its strategic collaboration with VarmX BV, as well as growth in newer therapies such as ANDEMBRY and HEMGENIX. For now, the shares still have some room to run, but much will depend on whether earnings can catch up with the rebound in sentiment.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
